AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2041-4889
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells ; volume:10 ; number:5 ; day:1 ; month:5 ; year:2019 ; pages:1-12 ; date:5.2019
Cell death & disease ; 10, Heft 5 (1.5.2019), 1-12, 5.2019
- Klassifikation
-
Medizin, Gesundheit
- Urheber
-
Kim, Donghwa
Bach, Duc-Hiep
Fan, Yan-Hua
Luu, Thi-Thu-Trang
Hong, Ji-Young
Park, Hyen Joo
Lee, Sang Kook
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41419-019-1601-6
- URN
-
urn:nbn:de:101:1-2019052419575869932786
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:52 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Kim, Donghwa
- Bach, Duc-Hiep
- Fan, Yan-Hua
- Luu, Thi-Thu-Trang
- Hong, Ji-Young
- Park, Hyen Joo
- Lee, Sang Kook
- SpringerLink (Online service)
Ähnliche Objekte (12)
Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer
Correction: The HDAC inhibitor, MPT0E028, enhances erlotinib induced cell death in EGFR-TKI-resistant NSCLC cells
EGFR T790M mutation as a novel target for immunotherapy against EGFR-TKI-resistant non-small cell lung cancer
CXCR1+ neutrophil infiltration orchestrates response to third-generation EGFR-TKI in EGFR mutant non-small-cell lung cancer
Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer
The role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancer
Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
EGFR plasma mutation in prediction models for resistance with EGFR TKI and survival of non-small cell lung cancer
Role of PARP1-mediated autophagy in EGFR-TKI resistance in non-small cell lung cancer
NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation
TKi | TKi
Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer
Correction: The HDAC inhibitor, MPT0E028, enhances erlotinib induced cell death in EGFR-TKI-resistant NSCLC cells
EGFR T790M mutation as a novel target for immunotherapy against EGFR-TKI-resistant non-small cell lung cancer
CXCR1+ neutrophil infiltration orchestrates response to third-generation EGFR-TKI in EGFR mutant non-small-cell lung cancer
Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer
The role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancer
Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
EGFR plasma mutation in prediction models for resistance with EGFR TKI and survival of non-small cell lung cancer
Role of PARP1-mediated autophagy in EGFR-TKI resistance in non-small cell lung cancer
NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation
TKi | TKi
Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer
Correction: The HDAC inhibitor, MPT0E028, enhances erlotinib induced cell death in EGFR-TKI-resistant NSCLC cells
EGFR T790M mutation as a novel target for immunotherapy against EGFR-TKI-resistant non-small cell lung cancer
CXCR1+ neutrophil infiltration orchestrates response to third-generation EGFR-TKI in EGFR mutant non-small-cell lung cancer
Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer
The role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancer
Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
EGFR plasma mutation in prediction models for resistance with EGFR TKI and survival of non-small cell lung cancer
Role of PARP1-mediated autophagy in EGFR-TKI resistance in non-small cell lung cancer
NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation